GLOW70 (BPC-157 10mg + GHK-CU 50mg + TB-500 10mg)

Buy high-purity GLOW70 stack in Australia (BPC-157 10mg + GHK-Cu 50mg + TB-500 10mg, 70mg total). Third-party lab tested at >99% purity. Australian-domestic shipping, AUD pricing, supplied for laboratory research use only.

About the GLOW70 stack

GLOW70 is a three-compound research stack co-lyophilised in a single vial: 10mg BPC-157 (a pentadecapeptide derived from gastric juice protein BPC), 50mg GHK-Cu (a copper-binding tripeptide), and 10mg TB-500 (a 17-amino-acid fragment of thymosin β-4). The combination assembles three of the most extensively studied peptides in regenerative, dermal and connective-tissue research into a single working unit, sized to the typical mass ratios used in published animal-model and cell-culture protocols. GLOW70 is a popular tool when researchers want to examine angiogenic, copper-dependent collagen-synthesis and actin-remodelling pathways in parallel rather than across separate vials.

Optic Labs supplies GLOW70 in Australia as a co-lyophilised powder, 70mg total, third-party HPLC verified at >99% purity for each constituent peptide. The stack is supplied strictly for laboratory research use only and is not intended for human consumption, clinical, cosmetic, diagnostic or veterinary application.

Product specifications

• Compound: BPC-157 (10mg) + GHK-Cu (50mg) + TB-500 (10mg) co-lyophilised stack
• BPC-157: CAS 137525-51-0, ~1419.5 g/mol, pentadecapeptide
• GHK-Cu: CAS 49557-75-7 (peptide) / 89030-95-5 (copper-bound), ~340.4 g/mol (free peptide), Gly-His-Lys with Cu²⁺
• TB-500: CAS 77591-33-4, 17-amino-acid fragment of thymosin β-4
• Form: Lyophilised powder (co-formulated)
• Purity: >99% by HPLC for each peptide
• Available size: 70mg total per vial (10mg BPC-157 + 50mg GHK-Cu + 10mg TB-500)
• Storage: 2–8°C, protect from light. Reconstituted: 2–8°C, used within 30 days.
• Origin: Manufactured to research-grade specifications, third-party HPLC verified
• Shipping: Australia-wide domestic dispatch from Sydney, NSW

Research background

The three peptides in GLOW70 are studied across overlapping but distinct repair and regenerative pathways. BPC-157 is characterised in the literature for angiogenic, nitric-oxide and growth-factor signalling; GHK-Cu for copper-dependent collagen synthesis, antioxidant gene expression and dermal remodelling; TB-500 for actin sequestration, cell migration and microvascular development. Combining them is a common research design when investigators want to probe parallel pathway engagement in connective-tissue, dermal and wound-healing models.

• BPC-157: tendon, ligament and gastrointestinal injury models examining fibroblast outgrowth and VEGF/eNOS signalling.
• GHK-Cu: copper-binding tripeptide research on collagen and elastin synthesis in dermal fibroblasts and ex-vivo skin models.
• GHK-Cu: gene-expression studies in cultured cells reporting modulation of antioxidant, anti-inflammatory and tissue-remodelling pathways.
• TB-500: G-actin sequestration and actin-cytoskeleton remodelling research relevant to cell migration.
• TB-500: cardiac, dermal, corneal and hair-follicle research examining endothelial and keratinocyte migration.
• Combined-peptide protocols in rodent wound and musculoskeletal-injury models examining repair time-course versus single-peptide arms.
• Skin and dermal-research designs examining whether BPC-157 + GHK-Cu + TB-500 produces additive effects on fibroblast activity and microvasculature.

For deeper background, see our BPC-157 complete research guide, our GHK-Cu copper peptide guide and our TB-500 research guide. Researchers working with reconstitution should also reference our peptide reconstitution guide.

Reconstitution and handling

GLOW70 is co-lyophilised — all three peptides dissolve together when the vial is reconstituted. Use sterile bacteriostatic water. Adding 3mL of bacteriostatic water to a 70mg vial yields approximately 23.3mg/mL total peptide, which corresponds to 3.33mg/mL BPC-157, 16.67mg/mL GHK-Cu and 3.33mg/mL TB-500. A 5mL reconstitution gives 14mg/mL total (2mg/mL BPC-157, 10mg/mL GHK-Cu, 2mg/mL TB-500), which is often more convenient for protocols where smaller working volumes are dosed. Add diluent slowly down the side of the vial — do not inject directly onto the lyophilised cake — and allow the powder to dissolve without vigorous shaking. Reconstituted GLOW70 should be stored at 2–8°C, protected from light, and used within 30 days. For dilution maths for any working volume, see our peptide reconstitution calculator guide and our peptide storage guide.

Commonly stacked research peptides

Researchers using GLOW70 commonly hold its constituent peptides separately for protocols requiring different ratios, alongside related repair and anti-inflammatory tools:

• BPC-157 — single-compound vial for protocols at non-stack ratios.
• GHK-Cu — single-compound copper-peptide vial for collagen and dermal-research designs.
• TB-500 — single-compound thymosin β-4 fragment vial.
• BPC-157 + TB-500 blend — two-compound vial for repair-pathway research without the GHK-Cu arm.
• KLOW80 stack — four-compound stack adding KPV to the GLOW70 base for anti-inflammatory pathway coverage.

For broader stack-design context, see our peptide research stacks overview.

Frequently asked questions

Is GLOW70 legal in Australia?

None of the constituent peptides — BPC-157, GHK-Cu or TB-500 — is an approved therapeutic good in Australia, and none is registered with the Therapeutic Goods Administration (TGA). Optic Labs supplies GLOW70 strictly for laboratory research, development and analytical use — not for human consumption, clinical or cosmetic application. For a detailed overview of how research peptides sit within the Australian regulatory framework, see our guide to peptide legality and TGA compliance in Australia.

What is GLOW70?

GLOW70 is a co-lyophilised three-compound research stack containing 10mg BPC-157, 50mg GHK-Cu and 10mg TB-500 in a single vial. The three peptides are widely co-studied in regenerative, dermal and connective-tissue research. For background on each, see our BPC-157, GHK-Cu and TB-500 guides.

Why use GLOW70 instead of three separate vials?

A co-lyophilised stack reduces handling steps and reconstitution events when a protocol consistently uses all three peptides together at this 1:5:1 mass ratio. For protocols that require unequal ratios, single-peptide arms or dose-escalation across one peptide, separate BPC-157, GHK-Cu and TB-500 vials are the appropriate choice.

How much bacteriostatic water do I mix with a GLOW70 vial?

For a 70mg vial, 3mL of bacteriostatic water yields approximately 23.3mg/mL total peptide (3.33mg/mL BPC-157, 16.67mg/mL GHK-Cu, 3.33mg/mL TB-500). 5mL gives 14mg/mL total. See our reconstitution calculator guide for worked examples at other volumes.

How should reconstituted GLOW70 be stored?

Reconstituted GLOW70 should be stored at 2–8°C, protected from light, and used within 30 days. Lyophilised vials are stable at 2–8°C until reconstitution. For full handling guidance, see our peptide storage research guide.

Where does Optic Labs ship to?

Optic Labs ships Australia-wide from Sydney, NSW. Standard dispatch is next business day on orders received before the daily cut-off. International shipping is not currently offered.

Legal disclaimer

All products on this site are supplied for laboratory research, development or analytical use only. They are not for human consumption, clinical use, or any diagnostic, cosmetic or veterinary application. These products and statements have not been evaluated by the Therapeutic Goods Administration (TGA) or the APVMA and are not intended to diagnose, treat, cure or prevent any disease. Optic Labs is not a compounding pharmacy or manufacturing facility as defined under the Therapeutic Goods Act 1989, and is not a registered provider of scheduled medicines or therapeutic goods.